The use of cardiopulmonary bypass (CPB) results in the activation of leukocytes, release of neutrophil extracellular traps (NETs) and severe inflammation. We hypothesize that targeting of circulating cellfree DnA (cfDnA) by DNases might represent a feasible therapeutic strategy to limit cpB-associated side effects. Male Wistar rats (n = 24) underwent CPB with deep hypothermic circulatory arrest (DHCA) and were divided into 3 groups: control (group 1), one i.v. bolus DNase I before CPB start (group 2) and a second DNase I dose before reperfusion (group 3). We found a positive correlation between plasma cfDNA/NETs levels and compromised endothelial vasorelaxation after CPB. DNase I administration significantly diminished plasma cfDNA/NETs levels. Further, a dose-dependent improvement in endothelial function accompanied by significant reduction of circulating intercellular adhesion molecule (ICAM)-1 was observed. Rats of group 3 had significantly reduced plasma IL-6 levels and downregulated expression of adhesion molecules resulting in impaired leukocyte extravasation and reduced MPO activity in lungs. Mechanistically, digestion of NETs by DNase I significantly diminished NETs-dependent upregulation of adhesion molecules in human endothelial cells. Altogether, systemic DNase I administration during CPB efficiently reduced cfDNA/NETs-mediated endothelial dysfunction and inflammation and might represents a promising therapeutic strategy for clinical practice.
Results
Effect of DNase I on physiological parameters and compensatory drug application during cpB with DHCA. Blood samples were collected from rats before CPB (T1), before reperfusion (T2) and at the end of reperfusion (T3). The levels of electrolytes, glucose, lactate, O 2 and CO 2 are summarized in Table 1 . The counts of the major blood cell fractions white blood cells, i.e. red blood cells and platelets did not differ between the control group and DNase I-treated animals at T1-T3 (Supplementary Table 1 ). No differences in haemoglobin concentrations as well as haematocrit values were observed. Finally, the plasma levels of various organ-specific injury markers such as creatinine, urea and uric acid (kidney), aspartate transaminase and alanine transaminase (liver), alpha-amylase (pancreas), neuron-specific enolase (neurons) as well as lactate dehydrogenase at the end of the CPB procedure (T3) were not affected by DNase I treatment (Supplementary Table 2 ). In contrast, cardiac troponin T was not detected in plasma samples of all experimental groups suggesting absence of CPB-induced cardiac injury during and at the end of surgery (not shown).
Heart rate and MAP values were similar in all experimental groups ( Supplementary Fig. 1 ). For norepinephrine (Arterenol) which was given to prevent a sustained CPB-induced fall of MAP we observed no differences in the amounts applied to animals that received DNase I versus controls ( Supplementary Fig. 2 ). Moreover, application of sodium bicarbonate or TRIS (Trometamol) to prevent metabolic acidosis was not necessary throughout the entire CPB procedure in any animal of the examined experimental groups.
impact of DNase I application on plasma cfDnA levels and plasma DNase activity. Plasma levels of cfDNA were quantified at defined times ( Fig. 1a ). CPB with DHCA strongly increased plasma cfDNA levels reaching a maximum at T3 (24.4-fold increase, P < 0.001 vs. T1). It has previously been reported that DNase I is rapidly inactivated by serum proteins 22 . Thus, DNase I therapy before CPB prevented cfDNA increase at T2 (17-fold reduction vs. Control, P < 0.001) but did not influence reperfusion-associated cfDNA elevation at T3. In contrast, two boli of DNase I, i.e. before CPB and reperfusion, largely suppressed cfDNA increase at T2 as well as T3 (13-fold reduction vs. Control, P < 0.001), indicating that DNase I exerts short-term effects. Rats receiving one bolus of DNase I displayed increased DNase activity only on T2 (1.7-fold increase, P < 0.01), whereas the activity at T3 was comparable to that found in control animals without DNase I treatment. In contrast, DNase I activity was found to be significantly increased after 60 min of reperfusion when the rats received a second bolus of DNase I (1.6-fold increase, P < 0.001; Fig. 1b ).
Vascular reactivity studies.
To study the effects of cfDNA on the endothelium, functional analyses were performed. Endothelium-dependent vasorelaxation in response to acethylcholine (ACh) was impaired in control rats after CPB with DHCA ( Fig. 2a ). DNase I treatment before CPB slightly improved vasorelaxation whereas significant improvement of vasorelaxation could be observed in aortic rings of rats that received a second dose of T1  T2  T3  T1  T2  T3  T1  T2 DNase I. Relaxation to ACh was inhibited in all groups in the presence of the NO synthase inhibitor L-NNA (not shown), confirming the dependence on NO. In turn, endothelium-independent vasorelaxation induced by the NO-donor SNAP was similar in all groups (Fig. 2b ).
There was a positive correlation between plasma cfDNA levels at the end of reperfusion (T3) and the extent of vasorelaxation after stimulation with 10 µM ACh (Pearson's r = 0.499, P = 0.025; Fig. 2c ). In addition, the activity of eNOS, which reflects endothelial function, was lowest in control animals and tended to increase in the aortas of rats receiving DNase I (P = 0.05; Fig. 2d ). The protective effect of DNase I-based therapy during CPB on vascular function could be confirmed by determining the levels of circulating ICAM-1 ( Fig. 2e ). Plasma levels of ICAM-1 were strongly upregulated after reperfusion in all groups and peaked in control animals (2.48-fold increase vs. T1). The CPB-induced upregulation of plasma ICAM-1 levels was significantly attenuated at T3 in animals that received DNase I yet no dose dependency was observed (1.9-fold and 1.5-fold reduction in groups 2 and 3, P = .04 vs. Control). These results suggest a protective effect of DNase I on vascular function.
Effect of DNase I on inflammation.
To evaluate the impact of DNase I administration on CPB-induced inflammation, plasma levels of IL-6, TNF-α, IFN-ɣ and IL-10 were quantified ( Fig. 3 ). All cytokines markedly increased at T3 and significant reduction of IL-6 was found in rats that received two doses of DNase I (4-fold, P = 0.04 vs. Control). No further significant changes were detected. As the endothelium contributes to leukocyte recruitment, the expression of inflammatory markers in the aortic endothelium was examined. DNase I (two doses) significantly downregulated vascular expression of ICAM-1 and VCAM-1 (2.2-fold and 1.9-fold vs. Control, P < 0.05), but did not change the expression of inducible nitric oxide synthase (iNOS), which is upregulated by pro-inflammatory cytokines and implicated in endothelial dysfunction 23 , as well as IL-6, TNF-α or IL-10, respectively ( Fig. 4a ). To further evidence that cfDNA comprise mainly NETs-derived DNA, which in turn causes endothelial activation, we performed additional in vitro experiments. Treatment of human endothelial cells with NETs augmented the expression of ICAM-1 and VCAM-1 (Fig. 4b ). However, these effects were not observed when cells were treated with DNase I-digested NETs or DNase I alone, respectively, demonstrating again that NETs degradation by DNases indeed counteracts endothelial activation.
Next, we investigated if diminished endothelial activity upon DNase I administration is consequently reflected by a reduced number of extravasated leukocytes. In this regard, we found a significant reduction in the number of infiltrated CD45-positive leukocytes in lung tissue of DNase I-treated rats compared to controls ( Fig. 5a ,b) supporting diminished leukocyte recruitment. Furthermore, the number of MPO-positive cells ( Fig. 5c ) as well as MPO activity ( Fig. 5d ) in lungs of DNase I-treated rats were significantly reduced. Overall, the effects of DNase I were more pronounced when two doses were applied.
Discussion
Despite major improvements in circuit design, oxygenators and the advent of heparin-bonded surfaces, the inflammatory response to CPB remains a clinical concern. There have been several attempts to attenuate postoperative cytokine release including anti-inflammatory therapy 24 , modifications in the bypass circuit 25 or changing temperature management in CPB 26 .
Activation of neutrophils and the consecutive release of NETs seem to play a pivotal role in inflammatory reactions. NETs were first discovered in 2004 as a unique form of cell death, distinct from necrosis or apoptosis 27 . Although NETs were originally believed to trap, immobilize and kill microbes, recent studies have revealed novel roles of NETs in coagulation activation and tissue damage 4, 5 . Additionally, I/R-triggered cfDNA/NETs release www.nature.com/scientificreports www.nature.com/scientificreports/ has already been reported 18, 28 . Here, cfDNA/NETs levels were found to be strongly increased after the reperfusion of rats that underwent CPB with DHCA. Qi et al. showed a significant correlation of neutrophil activation (S100A12) and elevation in serum cfDNA, suggesting a major contribution of neutrophil-derived cfDNA to elevated serum cfDNA concentrations 3 . As we did not find any alteration in cardiac troponin levels, increase in plasma cfDNA might largely derive from NETing neutrophils and probably to a small extend from necrotic tissue. Besides reactive oxygen species, NETs-associated components including histones, elastase and MPO may trigger endothelial injury, contributing to tissue injury in major organs 3, 16, 29, 30 . Indeed, high levels of soluble ICAM-1 were detected after reperfusion accompanied by impaired vasorelaxation in control animals indicating vascular injury. In line with these results, in a recent pilot study with patients who underwent cardiac surgery with CPB, we found significantly elevated cfDNA/NETs levels immediately after surgery that sustained until at least day 5 post-surgery 6 . Of note, plasma cfDNA/NETs levels increased with the duration of CPB support and high cfDNA/NETs concentrations strongly correlated with levels of soluble ICAM-1, which is a valuable biomarker of endothelial activation and damage. It might therefore be speculated, that enzymatic cfDNA/NETs degradation might represent a feasible strategy to limit collateral damage after on-pump cardiac surgery. In this regard, Pulmozyme ® (recombinant human DNase I (rhDNase I)), has already been used in multiple animal models of thrombosis 4,31 , as well as in various models of I/R injury 28 . Treatment with DNase I significantly reduces inflammation and thrombosis as evidenced by attenuated oxidative stress, apoptosis, and tissue damage after intestinal I/R injury 28, 32 . Although DNase I efficiently degrades cfDNA it has been suggested that it does not eliminate extracellular histones, which are also known to possess cytotoxic activity 33 . Here, DNase I application before CPB prevented cfDNA/NETs increase after DHCA but failed to inhibit cfDNA/NETs elevation after reperfusion, which might be explained by the relatively short half-life of DNases due to their rapid inactivation by serum components, such as monomeric actin 22 . In contrast, a second dose of DNase I before reperfusion markedly abolished a later increase in cfDNA/NETs. As plasma cfDNA levels were found to largely reach baseline levels, our results strongly support the feasibility of i.v. administrated DNase I for cfDNA/NETs degradation. More importantly, cfDNA/NETs degradation, especially before reperfusion, significantly improved vessel function arguing against toxic side effects of histones or NETs-associated proteases, respectively. DNase I significantly diminished plasma IL-6 levels and leukocyte infiltration in the lung, as evidenced by a reduced number of CD45-positive cells and diminished pulmonary MPO activity, being in line with the findings of Merza et al., who showed that NETs degradation reduces inflammation and neutrophil recruitment 34 . The protective effects of DNase I after i.v. administration are summarized in Fig. 6 . We propose that CPB and reperfusion trigger neutrophil activation and consequently the release of NETs. In accordance with data reported by Folco et al., we demonstrate that NETs promote endothelial activation in vivo and in vitro by upregulating the expression of adhesion molecules and pro-inflammatory cytokines 15 . However, in contrast to the results reported by Saffarzadeh et al., we did not find evidence for NETs-mediated cytotoxic effects on human endothelial cells (unpublished results) 16 . This finding might be explained by the concentration of NETs used in our experiments, which was 3-to 10-fold lower than the www.nature.com/scientificreports www.nature.com/scientificreports/ concentration found to have a toxic effect. Although in vivo effects of cfDNA/NETs could not be fully reproduced in vitro, the improvement of endothelial function in DNase I-treated rats strongly supports the hypothesis that NETs damage the endothelium. Here, DNase I efficiently degraded CPB-induced cfDNA/NETs, thus reducing endothelial cell activation and tissue/endothelial injury.
However, our study has several limitations that need to be considered. First, cardiac arrest was induced by deep hypothermia and not by cardioplegia. Our well-established rat model incorporates DHCA, which is still successfully used in modern aortic arch surgery. The exposition of organs to hypothermia reduces energy consumption and arrests cellular metabolism thus ensuring tissue integrity, but coincidentally it induces global I/R. Our standardized model can reproduce pathophysiological alterations that are associated with SIRS and I/R and helps to investigate novel therapeutic strategies in a preclinical setting 35 . Secondly, due to restrictions of our experimental proposal, animals had to be sacrificed at the end of CPB. Therefore, it would be worthwhile to investigate long-term effects of DNase I in this animal model. Nevertheless, the results of this study provide strong evidence for anti-inflammatory, vasculoprotective effects of i.v. administrated DNase I although efficacy in surgical patients was not evidenced and should be further evaluated. Altogether, this strategy might represent a possible therapeutic tool for the treatment of high-risk cardiac patients with on-pump surgery.
Methods
Animals and study design. This study was approved by the local authority LANUV (Landesamt für Natur, Umwelt und Verbraucherschutz NRW; AZ84-02.04.2014.A103) and carried out in accordance with German and European guidelines of laboratory animal care. 24 male Wistar rats weighing between 510 and 525 g (Janvier Breeding Center, France) were randomly assigned to three experimental groups: one control group undergoing CPB with DHCA (group 1), one group undergoing CPB with DHCA that received an i.v. bolus of DNase I (Pulmozyme ® , Roche, 5 mg/kg body weight) before CPB (group 2), and one group undergoing CPB with DHCA that received DNase I before CPB and a second bolus after rewarming/before reperfusion, respectively (group 3). This DNase I dose was previously found to effectively degrade plasma cfDNA/NETs 18, 36 . Two animals with low haemoglobin concentration during the procedure (Hb < 5.0 mg/dL) caused by a diffuse bleeding at the insertion Measurement of endothelial function. The thoracic aorta was cut into four segments (4 mm width).
Ring segments were mounted between two stainless steel hooks in individual organ baths (Hugo Sachs Elektronik, Germany) containing 10 ml of modified Krebs-Henseleit buffer (in mM: 118 NaCl, 5 KCl, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 24.9 NaHCO 3 , 2.5 CaCl 2 , and 11.0 glucose; pH 7.4) at 37 °C bubbled with 95% O 2 /5% CO 2 . The rings were equilibrated for 40 min under a resting tension of 1 g to allow development of a stable basal tone. Stimulation of rings with 60 mM KCl was repeated three times until contractile responses were stable and uniform. Indomethacin (10 µM) was present in the experiments to inhibit prostaglandin synthesis. To inhibit the activity of endothelial nitric oxide synthase (eNOS), some rings were pretreated with 100 µM N G -nitro-L-Arginine (L-NNA). All vessels were preconstricted with 0.1 µM phenylephrine (PE). Ligand-stimulated receptor-mediated NO bioavailability was assessed by a concentration-dependent relaxation to acetylcholine (ACh, 1 nM-10 µM). To study endothelium-independent vasorelaxation, aortic rings preconstricted with PE were treated with the NO donor S-Nitroso-N-acetyl-D,L-penicillamine (SNAP; 0.1 nM-10 µM).
Relaxation responses to ACh and SNAP were expressed as percentage of relaxation from a submaximal PE-induced constriction and concentration-response curves were obtained.
Analysis of electrolytes, gases and cell counts in arterial blood. The analysis of electrolytes, gases
and cell counts in arterial blood samples was performed using the ABL 700 (Radiometer Copenhagen) and Vet abc (Scil animal care) devices. Determination of tissue and plasma MPO activity. Immediately after euthanization, the lungs were removed and snap frozen in liquid nitrogen. MPO activity in lung tissues was determined by using the MPO Activity Assay Kit II (PromoCell) according to the manufacturer's instructions. Fluorescence-based kinetic measurements at excitation and emission wavelengths of 485 nm and 530 nm were performed using a microplate reader (Victor X3, Perkin Elmer). Units of MPO activity per 1 min were calculated from a standard curve using fluorescein standard.
Immunofluorescence staining. Frozen lung tissue samples of rats were sectioned at 7 µm intervals and fixed with 4% paraformaldehyde. For the detection of MPO-positive cells (neutrophils, monocytes), sections were permeabilized with 0.2% Triton X-100 and incubated with 5% normal goat serum + 0.5% BSA + 0.2% TritonX-100 in PBS in order to block unspecific binding. Sections were further incubated with anti-MPO antibody (1:100, Abcam) for 1 h followed by additional incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000, Cell Signaling Technology) overnight at 4 °C.
For the detection of leukocytes, a mouse monoclonal anti-rat CD45 antibody was used (clone OX-1, 1:20, BD Pharmingen). Then, slides were further incubated with Alexa Fluor 555-conjugated goat anti-mouse IgG (H + L) secondary antibody (1:1000, Thermo Fisher) for 1 h at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenyl indole (DAPI) and slides were mounted in fluorescence mounting medium (Dako). Tissue sections were examined using an inverted microscope (Eclipse Ti-U 100, Nikon). Signal intensity of CD45 immunolabeling in ten random fields was quantified as mean value and averaged using the Image J analysis software.
Quantitative real-time PCR (qPCR). RNA was extracted from thoracic aorta tissue using TRIzol (Invitrogen) and the RNeasy Mini Kit (Qiagen). Reverse transcription to cDNA was performed using Quantitect Reverse Transcription Kit (Qiagen). For qPCR, the GoTaq PCR Master Mix (Promega) and self-designed primers against mRNA transcripts encoding rat ICAM-1, VCAM-1, TNF-α, IL-6, IL-10, iNOS as well as human ICAM-1 and VCAM-1 have been used. Expression levels for each mRNA were normalized to the mRNA level of 18 S rRNA (rat) or GAPDH (human), respectively. The relative mRNA expression level was calculated using the comparative threshold cycle method (∆C T ).
Western blot analyses. Proteins were extracted from thoracic aorta tissue using Cell Lysis Buffer (Cell Signaling) supplemented with proteinase and phosphatase inhibitors (Complete Mini and PhosSTOP, Roche). For Western blot, 50 µg of total protein was loaded on 7% polyacrylamide gels and blotted onto nitrocellulose membranes via tank blot. Expression levels of total eNOS and eNOS phosphorylated at Ser1177 were analysed using antibodies from BD Biosciences (#610297) and Cell Signaling Technology (#9570), respectively. Protein bands were visualized using a chemiluminescence system (Thermo Fisher). Band intensities were quantified using ImageJ software (National Institutes of Health).
Statistical analyses.
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). Data are presented as Data are presented as mean ± SEM. Data sets were assessed for normality using the Kolmogorov-Smirnov test. Normally distributed unpaired data of multiple groups were analyzed using one-way ANOVA with Newman Keuls post-hoc test. The Kruskal-Wallis test was used for nonparametric values. Correlations were evaluated by the Pearson correlation coefficient (r). P-values < 0.05 were considered as statistically significant.
